700. Identification and Whole-Genome Sequencing (WGS) of Meropenem-Vaborbactam (MV) Resistant Klebsiella pneumoniae (MVRKP) Among Patients Without Prior Exposure to MV: Collateral Damage

BACKGROUND: MV is a newly approved β-lactam/β-lactamase inhibitor combination (BLIC) for the treatment of complicated urinary tract infections (cUTI). Vaborbactam is a cyclic boronic acid BLI that was mainly developed as a potent inhibitor of KPC carbapenemases and other Ambler class A&C enzymes...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Open Forum Infect Dis
Päätekijät: Yasmin, Mohamad, Chen, Liang, Marshall, Steven H, Kreiswirth, Barry N, Perez, Federico, Bonomo, Robert A
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2018
Aiheet:
Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6254692/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.707
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia